Health impact and cost effectiveness of implementing gender-neutral HPV vaccination in Japan

References

• de Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–670. doi:10.1002/ijc.30716.
   PubMed Web of Science ®Google Scholar
• Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12–23. doi:10.1016/j.vaccine.2012.07.055.
   PubMed Web of Science ®Google Scholar
• Kitamura T, Suzuki M, Shigehara K, et al. Prevalence and risk factors of human papillomavirus infection among Japanese female people: a nationwide epidemiological survey by self-sampling. Asian Pac J Cancer Prev. 2021;22(6):1843–1849. doi:10.31557/APJCP.2021.22.6.1843.
   PubMedGoogle Scholar
• Palmer M, Katanoda K, Saito E, et al. Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: a systematic review and meta-analysis. Vaccine. 2022;40(41):5971–5996. doi:10.1016/j.vaccine.2022.07.052.
   PubMed Web of Science ®Google Scholar
• Matsuzawa Y, Kitamura T, Suzuki M, et al. Prevalence, genotype distribution, and predictors against HPV infections targeted by 2-, 4-, 9-Valent HPV vaccines among Japanese males. Vaccines (Basel). 2020;8(2):221. doi:10.3390/vaccines8020221.
   PubMed Web of Science ®Google Scholar
• ICO/IARC Information Centre on HPV and Cancer. Japan: human papillomavirus and related cancers, fact sheet 2023: HPV Information Centre; 2023 [updated March 10, 2023; cited 2023 March 30]. Available from: https://hpvcentre.net/statistics/reports/JPN_FS.pdf.
   Google Scholar
• Kawado M, Hashimoto S, Ohta A, et al. Estimating nationwide cases of sexually transmitted diseases in 2015 from sentinel surveillance data in Japan. BMC Infect Dis. 2020;20(1):77. doi:10.1186/s12879-020-4801-x.
   PubMed Web of Science ®Google Scholar
• Ujiie M, Kitano T, Tsuzuki S. Changing trends in HPV vaccination in Japan. Hum Vaccine Immunother. 2022;18(1):1–3. doi:10.1080/21645515.2021.1986333.
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Mori R, Jacklin P, et al. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis. BJOG. 2012;119(2):177–186. doi:10.1111/j.1471-0528.2011.03036.x.
   PubMed Web of Science ®Google Scholar
• Konno R, Sasagawa T, Fukuda T, et al. Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women. Int J Gynecol Cancer. 2010;20(3):385–392. doi:10.1111/IGC.0b013e3181d189b8.
   PubMed Web of Science ®Google Scholar
• Yamabe K, Singhal PK, Abe M, et al. The cost-effectiveness analysis of a quadrivalent human papillomavirus vaccine (6/11/16/18) for females in Japan. Value Health Reg Issues. 2013;2(1):92–97. doi:10.1016/j.vhri.2013.02.001.
   PubMedGoogle Scholar
• Gilmour S, Kanda M, Kusumi E, et al. HPV vaccination programme in Japan. Lancet. 2013;382(9894):768. doi:10.1016/S0140-6736(13)61831-0.
   PubMed Web of Science ®Google Scholar
• Hanley SJ, Yoshioka E, Ito Y, et al. HPV vaccination crisis in Japan. Lancet. 2015;385(9987):2571. doi:10.1016/S0140-6736(15)61152-7.
   PubMed Web of Science ®Google Scholar
• The Ministry of Health Labour and Welfare. 2013. Available from: https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou28/pdf/kankoku_h25_6_01.pdf.
   Google Scholar
• Saitoh A, Okabe N. Recent progress and concerns regarding the Japanese immunization program: addressing the "vaccine gap”. Vaccine. 2014;32(34):4253–4258. doi:10.1016/j.vaccine.2014.06.022.
   PubMed Web of Science ®Google Scholar
• Haruyama R, Obara H, Fujita N. Japan resumes active recommendations of HPV vaccine after 8.5 years of suspension. Lancet Oncol. 2022;23(2):197–198. doi:10.1016/S1470-2045(22)00002-X.
   PubMed Web of Science ®Google Scholar
• Ujiie M. Resumption of active recommendation of the human papillomavirus vaccine in Japan and future challenges for the national immunization program. Hum Vaccin Immunother. 2022;18(6):2090777. doi:10.1080/21645515.2022.2090777.
   PubMed Web of Science ®Google Scholar
• Ueda Y, Enomoto T, Sekine M, et al. Japan’s failure to vaccinate girls against human papillomavirus. Am J Obstet Gynecol. 2015;212(3):405–406. doi:10.1016/j.ajog.2014.11.037.
   PubMed Web of Science ®Google Scholar
• Sekine M, Kudo R, Adachi S, et al. Japanese crisis of HPV vaccination. Int J Pathol Clin Res. 2016;2(2):039. doi:10.23937/2469-5807/1510039.
   Google Scholar
• Nakagawa S, Ueda Y, Yagi A, et al. Corrected human papillomavirus vaccination rates for each birth fiscal year in Japan. Cancer Sci. 2020;111(6):2156–2162. doi:10.1111/cas.14406.
   PubMed Web of Science ®Google Scholar
• Simms KT, Hanley SJB, Smith MA, et al. Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study. Lancet Public Health. 2020;5(4):e223–e234. doi:10.1016/S2468-2667(20)30010-4.
   PubMed Web of Science ®Google Scholar
• Sekine M, Yamaguchi M, Kudo R, et al. Suspension of proactive recommendations for HPV vaccination has led to a significant increase in HPV infection rates in young Japanese women: real-world data. Lancet Reg Health West Pac. 2021;16:100300. doi:10.1016/j.lanwpc.2021.100300.
   PubMedGoogle Scholar
• Yagi A, Ueda Y, Ikeda S, et al. The looming health hazard: a wave of HPV-related cancers in Japan is becoming a reality due to the continued suspension of the governmental recommendation of HPV vaccine. Lancet Reg Health West Pac. 2022;18:100327. doi:10.1016/j.lanwpc.2021.100327.
   PubMedGoogle Scholar
• Yagi A, Ueda Y, Nakagawa S, et al. Can Catch-Up vaccinations fill the void left by suspension of the governmental recommendation of HPV vaccine in Japan? Vaccines (Basel). 2022;10(9):1455. doi:10.3390/vaccines10091455.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Unger ER. Human papillomavirus vaccination. N Engl J Med. 2023;388(19):1790–1798. doi:10.1056/NEJMcp2108502.
   PubMed Web of Science ®Google Scholar
• Mikamo H, Yamagishi Y, Murata S, et al. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: a randomized, phase 3, placebo-controlled study. Vaccine. 2019;37(12):1651–1658. doi:10.1016/j.vaccine.2019.01.069.
   PubMed Web of Science ®Google Scholar
• Ueda Y, Yagi A, Ikeda S, et al. Beyond resumption of the Japanese government’s recommendation of the HPV vaccine. Lancet Oncol. 2018;19(12):1563–1564. doi:10.1016/S1470-2045(18)30573-4.
   PubMed Web of Science ®Google Scholar
• Yagi A, Ueda Y, Nakagawa S, et al. Potential for cervical cancer incidence and death resulting from Japan’s current policy of prolonged suspension of its governmental recommendation of the HPV vaccine. Sci Rep. 2020;10(1):15945. doi:10.1038/s41598-020-73106-z.
   PubMed Web of Science ®Google Scholar
• Brisson M, Van de Velde N, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics. 2009;12(5–6):343–351. doi:10.1159/000214924.
   PubMed Web of Science ®Google Scholar
• Canfell K, Chesson H, Kulasingam SL, et al. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine. 2012;30(5):F157–67. doi:10.1016/j.vaccine.2012.06.091.
   PubMedGoogle Scholar
• Ng SS, Hutubessy R, Chaiyakunapruk N. Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination. Vaccine. 2018;36(19):2529–2544. doi:10.1016/j.vaccine.2018.03.024.
   PubMed Web of Science ®Google Scholar
• de Figueiredo A, Simas C, Karafillakis E, et al. Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study. Lancet. 2020;396(10255):898–908. doi:10.1016/S0140-6736(20)31558-0.
   PubMed Web of Science ®Google Scholar
• Lelliott M, Sahker E, Poudyal H. A review of parental vaccine hesitancy for human papillomavirus in Japan. J Clin Med. 2023;12(5):2004. doi:10.3390/jcm12052004.
   PubMed Web of Science ®Google Scholar
• Organisation for Economic Co-operation and Development. Exchange rates [cited 2023 November 1]. Available from: https://data.oecd.org/conversion/exchange-rates.htm.
   Google Scholar
• Cody P, Tobe K, Abe M, et al. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study. BMC Infect Dis. 2021;21(1):11. doi:10.1186/s12879-020-05632-0.
   PubMed Web of Science ®Google Scholar
• Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of human papillomavirus (HPV) disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis. 2009;9(1):119. doi:10.1186/1471-2334-9-119.
   PubMedGoogle Scholar
• Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28(42):6858–6867. doi:10.1016/j.vaccine.2010.08.030.
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13(1):28–41. doi:10.3201/eid1301.060438.
   PubMed Web of Science ®Google Scholar
• The BROADEN study: burden of human papillomavirus-related head and neck cancers in Japan. Public health oral: epidemiology and risk factors. In: 35th International Papillomavirus Conference; Washington DC, 2023.
   Google Scholar
• National Cancer Registry. Cancer Statistics in Japan [cited 2023 April 1]. Available from: https://ganjoho.jp/reg_stat/statistics/data/dl/en.html.
   Google Scholar
• Shirobon Net. 2022 Medical Fee Score Table [cited 2023 October 2]. Available from: https://shirobon.net/medicalfee/latest/.
   Google Scholar
• Shiroiwa T, Igarashi A, Fukuda T, et al. WTP for a QALY and health states: more money for severer health states? Cost Eff Resour Alloc. 2013;11(1):22. doi:10.1186/1478-7547-11-22.
   PubMedGoogle Scholar
• Lin F, Kwong WJ, Shi S, et al. Assessing the health and economic outcomes of a 9-Valent HPV vaccination program in the United Kingdom. J Health Econ Outcomes Res. 2022;9(1):33289–33150. doi:10.26469/jheor.2022.33289.
   PubMedGoogle Scholar
• Cheung TH, Cheng SSY, Hsu D, et al. Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong. Hum Vaccin Immunother. 2023;19(2):2184605. doi:10.1080/21645515.2023.2184605.
   PubMed Web of Science ®Google Scholar
• Majed L, Bresse X, El Mouaddin N, et al. Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France. Vaccine. 2021;39(2):438–446. doi:10.1016/j.vaccine.2020.10.089.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Human papillomavirus vaccines: WHO position paper. Weekly Epidemiological Record. 2022;50(97):645–672.
   Google Scholar
• Chow EPF, Tabrizi SN, Fairley CK, et al. Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study. Lancet Infect Dis. 2021;21(10):1448–1457. doi:10.1016/S1473-3099(20)30687-3.
   PubMed Web of Science ®Google Scholar
• Elfstrom KM, Lazzarato F, Franceschi S, et al. Human papillomavirus vaccination of boys and extended catch-up vaccination: effects on the resilience of programs. J Infect Dis. 2016;213(2):199–205. doi:10.1093/infdis/jiv368.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Gray P, Louvanto K, et al. In 30 years, gender-neutral vaccination eradicates oncogenic human papillomavirus (HPV) types while screening eliminates HPV-associated cancers. Expert Rev Vaccines. 2022;21(6):735–738. doi:10.1080/14760584.2022.2064279.
   PubMed Web of Science ®Google Scholar
• Sundaram N, Voo TC, Tam CC. Adolescent HPV vaccination: empowerment, equity and ethics. Hum Vaccin Immunother. 2020;16(8):1835–1840. doi:10.1080/21645515.2019.1697596.
   PubMed Web of Science ®Google Scholar
• Vanska S, Luostarinen T, Baussano I, et al. Vaccination with moderate coverage eradicates oncogenic human papillomaviruses if a Gender-Neutral strategy is applied. J Infect Dis. 2020;222(6):948–956. doi:10.1093/infdis/jiaa099.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31(36):4550–4559. doi:10.1200/JCO.2013.50.3870.
   PubMed Web of Science ®Google Scholar
• Utada M, Chernyavskiy P, Lee WJ, et al. Increasing risk of uterine cervical cancer among young Japanese women: comparison of incidence trends in Japan, South Korea and Japanese-Americans between 1985 and 2012. Int J Cancer. 2019;144(9):2144–2152. doi:10.1002/ijc.32014.
   PubMed Web of Science ®Google Scholar
• Varga S, Wang X, Luttropp K, et al. Global burden of HPV-related cancers in men: a systematic literature review. J Clin Oncol. 2019;37(15_suppl):e13108–e13108. doi:10.1200/JCO.2019.37.15_suppl.e13108.
   Web of Science ®Google Scholar
• Union for International Cancer Control. TNM classification of malignant tumours. 8th ed. In: Wittekind C, Brierley JD, Gospodarowicz MK, editors. Wiley; 2017.
   Google Scholar